Numerous studies have demonstrated that CTCs in prostate and breast cancers are EpCAM-positive, indicating their prognostic value in the disease’s early and metastatic stages.26,27 Other epithelial-derived cancers, including pancreatic,28 colorectal,29 and hepatocellular cancers,30 also exhibit significant detection rates of EpCAM-positive CTCs. This evidence concerns the gene EPCAM and hepatocellular carcinoma.